Research Paper Volume 13, Issue 15 pp 19486—19509

A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer

class="figure-viewer-img"

Figure 7. The risk classifier serves as a favorable biomarker of resistance to chemotherapy. (A) The ratio of complete response (CR) from GSE18864 cohort, and (B) the ratio of breast cancer related events from GSE90505 cohort in the HIRS based groups. (C) The relationship between gene signature and IC50 of different molecules in BRCA cell lines. PD, progressive disease; PR, partial remission, SD stable disease.